The FDA has approved Watson's abbreviated new drug application (ANDA) to make a generic version of Bristol-Myers Squibb's antidepressant Serzone, the company announced. The approval covers the manufacturing and marketing of nefazodone HCl tablets in 100-, 150-, 200- and 250-mg doses, Watson said. The FDA also approved ANDAs for the drug submitted by Ivax, Mylan, Teva and Eon. Serzone had sales of $220 million in the 12-month period ending in June, according to IMS Data.